Document is current
Any future updates will be listed below
-
Authors
Aldawod, Hala
Patel, Arjun D.
Emara, Rasha
Liang, Dengpan https://orcid.org/0000-0001-9898-1836
Ho, Joshua S.
Amin, Toufiq Ul https://orcid.org/0000-0002-9093-4856
Tuhin, Md Tariqul Haque
Balgoname, Abdulmalek https://orcid.org/0000-0003-4221-9433
Kiani, Avishan
Ajlouny, Jumana M.
Felmlee, Melanie A.
Park, Miki S.
Jasti, Bhaskara R.
Chan, William K.
Uchizono, James A. https://orcid.org/0000-0002-5896-3905
Alhamadsheh, Mamoun M. https://orcid.org/0000-0003-4325-7044
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (5R01DA058024)
- License Information
-
More Information
Article History
Received: 26 July 2024
Accepted: 6 January 2025
First Online: 23 January 2025
Competing interests
: M.M.A. is a cofounder of Eidos Therapeutics and a co-inventor of AG10 (acoramidis, or ATTRuby™), a US FDA-approved drug for the treatment of TTR amyloid cardiomyopathy. M.M.A. has filed, as a sole inventor, a provisional patent application related to the development and application of the new prodrug technology. The remaining authors declare no competing interests.
